JP2017535794A - 免疫調節不全についてのマーカーとしてのｐｉｆ結合 - Google Patents

免疫調節不全についてのマーカーとしてのｐｉｆ結合 Download PDF

Info

Publication number
JP2017535794A
JP2017535794A JP2017543287A JP2017543287A JP2017535794A JP 2017535794 A JP2017535794 A JP 2017535794A JP 2017543287 A JP2017543287 A JP 2017543287A JP 2017543287 A JP2017543287 A JP 2017543287A JP 2017535794 A JP2017535794 A JP 2017535794A
Authority
JP
Japan
Prior art keywords
pif
seq
cells
immune
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017543287A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535794A5 (https=
Inventor
アール． バルネア，エイタン
アール． バルネア，エイタン
Original Assignee
バイオインセプト、エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/050532 external-priority patent/WO2016044493A1/en
Application filed by バイオインセプト、エルエルシー filed Critical バイオインセプト、エルエルシー
Publication of JP2017535794A publication Critical patent/JP2017535794A/ja
Publication of JP2017535794A5 publication Critical patent/JP2017535794A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rehabilitation Therapy (AREA)
JP2017543287A 2014-11-03 2015-11-03 免疫調節不全についてのマーカーとしてのｐｉｆ結合 Pending JP2017535794A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462074384P 2014-11-03 2014-11-03
US62/074,384 2014-11-03
US201562113298P 2015-02-06 2015-02-06
US62/113,298 2015-02-06
US201562211660P 2015-08-28 2015-08-28
US62/211,660 2015-08-28
PCT/US2015/050532 WO2016044493A1 (en) 2014-09-16 2015-09-16 Compositions and methods for treating acute radiation syndrome
USPCT/US2015/050532 2015-09-16
PCT/US2015/058877 WO2016073513A1 (en) 2014-11-03 2015-11-03 Pif binding as a marker for immune dysregulation

Publications (2)

Publication Number Publication Date
JP2017535794A true JP2017535794A (ja) 2017-11-30
JP2017535794A5 JP2017535794A5 (https=) 2018-12-13

Family

ID=55909715

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017543287A Pending JP2017535794A (ja) 2014-11-03 2015-11-03 免疫調節不全についてのマーカーとしてのｐｉｆ結合

Country Status (7)

Country Link
US (1) US20180318386A1 (https=)
EP (1) EP3215847A4 (https=)
JP (1) JP2017535794A (https=)
AU (2) AU2015343202A1 (https=)
CA (1) CA2965973A1 (https=)
IL (1) IL251667A0 (https=)
WO (1) WO2016073513A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017039751A1 (en) 2015-08-28 2017-03-09 Bioincept, Llc Mutant peptides and methods of treating subjects using the same
WO2017079430A1 (en) * 2015-11-03 2017-05-11 Bioincept, Llc Peptides and methods of treating endometriosis using the same
EP3341006A4 (en) 2015-08-28 2019-03-13 BioIncept LLC COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE
US20230190867A1 (en) * 2018-02-22 2023-06-22 Bioincept, Llc Methods of treating nash and compositions therefore
CN113640092A (zh) * 2020-04-23 2021-11-12 复旦大学 石蜡包埋组织样本的处理方法以及其质谱检测方法
US20230400471A1 (en) * 2020-10-15 2023-12-14 Bioincept, Llc Systems, compositions and methods of determining viability of embryos using the same
WO2025078961A1 (en) * 2023-10-13 2025-04-17 Gufic Biosciences Limited Composition and method for treatment of endometriosis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512953A (ja) * 2001-07-02 2005-05-12 バイオインセプト、エルエルシー 着床前因子の新しいアッセイ方法および着床前因子ペプチド
US20070136003A1 (en) * 2005-12-08 2007-06-14 Electronics And Telecommunications Research Institute Method and system of verifying protein-protein interaction using protein homology relationship
JP2008507283A (ja) * 2004-07-22 2008-03-13 ファイブ プライム セラピューティクス，インコーポレイテッド 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法
US20090081225A1 (en) * 2001-07-02 2009-03-26 Barnea Eytan R PIF peptides biologic activities, site of action, and the antibody to detect PIF
JP2014508164A (ja) * 2011-03-02 2014-04-03 バイオインセプト、エルエルシー 細胞内損傷の治療のための組成物および方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646003A (en) * 1994-03-23 1997-07-08 Barnea; Eytan R. Preimplantation factor
ATE374370T1 (de) * 1999-01-25 2007-10-15 Siemens Medical Solutions Diag Verfahren zur diagnose von endometriose
US7723289B2 (en) * 2003-10-22 2010-05-25 Bioincept, Llc PIF tetrapeptides
WO2006087722A1 (en) * 2005-02-17 2006-08-24 Hadasit Medical Research Services And Development Ltd. Bisphosphonates for treating endometriosis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512953A (ja) * 2001-07-02 2005-05-12 バイオインセプト、エルエルシー 着床前因子の新しいアッセイ方法および着床前因子ペプチド
US20090081225A1 (en) * 2001-07-02 2009-03-26 Barnea Eytan R PIF peptides biologic activities, site of action, and the antibody to detect PIF
JP2008507283A (ja) * 2004-07-22 2008-03-13 ファイブ プライム セラピューティクス，インコーポレイテッド 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法
US20070136003A1 (en) * 2005-12-08 2007-06-14 Electronics And Telecommunications Research Institute Method and system of verifying protein-protein interaction using protein homology relationship
JP2014508164A (ja) * 2011-03-02 2014-04-03 バイオインセプト、エルエルシー 細胞内損傷の治療のための組成物および方法

Also Published As

Publication number Publication date
EP3215847A1 (en) 2017-09-13
AU2019203459A1 (en) 2019-06-06
US20180318386A1 (en) 2018-11-08
CA2965973A1 (en) 2016-05-12
AU2015343202A1 (en) 2017-05-25
IL251667A0 (en) 2017-06-29
EP3215847A4 (en) 2018-02-14
WO2016073513A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
JP2017535794A (ja) 免疫調節不全についてのマーカーとしてのｐｉｆ結合
US20240101625A1 (en) Epha2 t-cell epitope agonists and uses therefore
JP7610535B2 (ja) セリアック病の診断、スクリーニング、および治療のための患者由来腸オルガノイドの使用
CN1842603B (zh) 选择适于wt1疫苗患者的方法
EP3634584B1 (en) Tumor-infiltrating t-cells for use in the treatment of cancer
EP3301107B1 (en) Novel peptides that bind to types of mhc class ii and their use in diagnosis and treatment
JP2011509676A (ja) ヒトＴｈ１７細胞の選択的分化、同定および調節
AU2019261780A1 (en) Compositions comprising gluten peptides and uses thereof
US10408840B2 (en) Method for predicting clinical effect of immunotherapy
WO2021160146A1 (zh) 靶向免疫检查点tim3结合肽及其应用
ES2425486T3 (es) Análisis de pronóstico para determinar la respuesta de células T a antígenos HLA y uso del mismo en el campo del trasplante de tejidos
Katz-Levy et al. Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs.
Ráki et al. Surface expression of transglutaminase 2 by dendritic cells and its potential role for uptake and presentation of gluten peptides to T cells
US20230013244A1 (en) Pif binding as a marker for immune dysregulation
US10527630B2 (en) Method for detecting antibody-secreting B cells specific for HLA
US20230349889A1 (en) Methods of Determining Immune Response
RU2852974C1 (ru) Анализ на предмет восстановления иммунных клеток
JP5757624B2 (ja) 抗アレルギー因子のスクリーニング方法
JP2023526144A (ja) 免疫細胞回復のためのアッセイ
JP2012233693A (ja) 宿主対移植片疾患の検査方法
AV et al. T-Regulatory Cells: The Recently Recognized Players of Immunomodulation

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20171026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181102

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200609